Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fresenius News Not All Bad For Affymax’s Omontys

This article was originally published in The Pink Sheet Daily

Executive Summary

Affymax investors were not pleased with the country’s largest dialysis provider pausing its pilot program of Omontys, but Affymax and analysts are bullish on prospects of a long-term contract developing.


Related Content

Takeda/Affymax Recall ESA Omontys After Patient Deaths
ESRD Market Snapshot: The Price Has To Be Right
Affymax Anticipates Broad Opportunity For Omontys With Both Small And Large Dialysis Providers


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts